Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Females ≥18 and \<65 years~* Clinical diagnosis of symptomatic acute VVC~* Positive KOH .At least one vulvovaginal sign (vulvovaginal erythema, edema, or excoriation).~* At least one vulvovaginal symptom (vulvovaginal itching, burning, or irritation)~* A minimum composite vulvovaginal signs and symptoms score of ≥6~* must be be able to swallow capsules~Exclusion Criteria:~* Evidence of major organ system disease~* History of cervical cancer~* History of diabetes mellitus~* Pregnant~* Recent use of systemic antifungal drugs or systemic antimicrobial therapy for any reason~* Recent use of drugs to treat vaginal infections~* Recent use of immunosuppressive therapies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VT-1161 300mg QD (Type: EXPERIMENTAL): None
- VT-1161 600mg QD (Type: EXPERIMENTAL): None
- VT-1161 600mg BID (Type: EXPERIMENTAL): None
- Fluconazole 150mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).